Exhaled nitric oxide and the management of childhood asthma: yet another promising biomarker "has been" or a misunderstood gem

Research output: Contribution to journalArticle

19 Citations (Scopus)
5 Downloads (Pure)

Abstract

Childhood asthma is a common chronic condition. Approximately five percent of all children in western countries are prescribed treatment with inhaled corticosteroids (ICS) to prevent asthma symptoms. Current guidelines advocate titrating ICS dose to symptoms but this approach is not without problem, e.g. how to discern asthmatic from non-asthmatic symptoms? And when to reduce ICS dose? This review describes the strengths and weaknesses of fractional exhaled nitric oxide (FENO) as an objective index for individualising asthma control in children. Epidemiological and mechanistic evidence suggest that FENO should be a promising biomarker for eosinophilic airway inflammation (a hall mark for asthma) but somewhat surprisingly, clinical trials in children have not consistently found benefit from adding FENO to a symptom-based approach to ICS treatment in children. There are a number of reasons why FENO has apparently failed to translate from promising biomarker to clinically useful tool, and one reason may be a lack of understanding of what merits a significant intrasubject change in FENO. This review describes the rise and apparent fall of FENO as biomarker for asthma and then focuses on more recent evidence which suggest that FENO may prove to have a role in the management of childhood asthma, and in particular preventing exacerbations.

Original languageEnglish
Pages (from-to)88-96
Number of pages9
JournalPaediatric Respiratory Reviews
Volume16
Issue number2
Early online date7 Aug 2014
DOIs
Publication statusPublished - Mar 2015

Fingerprint

Nitric Oxide
Asthma
Biomarkers
Adrenal Cortex Hormones
Clinical Trials
Guidelines
Inflammation
Therapeutics

Keywords

  • asthma
  • child
  • nitric oxide
  • respiratory symptoms

Cite this

@article{f1228d0b71ed4d5ba8c81165f5f75787,
title = "Exhaled nitric oxide and the management of childhood asthma: yet another promising biomarker {"}has been{"} or a misunderstood gem",
abstract = "Childhood asthma is a common chronic condition. Approximately five percent of all children in western countries are prescribed treatment with inhaled corticosteroids (ICS) to prevent asthma symptoms. Current guidelines advocate titrating ICS dose to symptoms but this approach is not without problem, e.g. how to discern asthmatic from non-asthmatic symptoms? And when to reduce ICS dose? This review describes the strengths and weaknesses of fractional exhaled nitric oxide (FENO) as an objective index for individualising asthma control in children. Epidemiological and mechanistic evidence suggest that FENO should be a promising biomarker for eosinophilic airway inflammation (a hall mark for asthma) but somewhat surprisingly, clinical trials in children have not consistently found benefit from adding FENO to a symptom-based approach to ICS treatment in children. There are a number of reasons why FENO has apparently failed to translate from promising biomarker to clinically useful tool, and one reason may be a lack of understanding of what merits a significant intrasubject change in FENO. This review describes the rise and apparent fall of FENO as biomarker for asthma and then focuses on more recent evidence which suggest that FENO may prove to have a role in the management of childhood asthma, and in particular preventing exacerbations.",
keywords = "asthma, child , nitric oxide, respiratory symptoms",
author = "Steve Turner",
note = "Copyright {\circledC} 2014 Elsevier Ltd. All rights reserved.",
year = "2015",
month = "3",
doi = "10.1016/j.prrv.2014.07.005",
language = "English",
volume = "16",
pages = "88--96",
journal = "Paediatric Respiratory Reviews",
issn = "1526-0542",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Exhaled nitric oxide and the management of childhood asthma

T2 - yet another promising biomarker "has been" or a misunderstood gem

AU - Turner, Steve

N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.

PY - 2015/3

Y1 - 2015/3

N2 - Childhood asthma is a common chronic condition. Approximately five percent of all children in western countries are prescribed treatment with inhaled corticosteroids (ICS) to prevent asthma symptoms. Current guidelines advocate titrating ICS dose to symptoms but this approach is not without problem, e.g. how to discern asthmatic from non-asthmatic symptoms? And when to reduce ICS dose? This review describes the strengths and weaknesses of fractional exhaled nitric oxide (FENO) as an objective index for individualising asthma control in children. Epidemiological and mechanistic evidence suggest that FENO should be a promising biomarker for eosinophilic airway inflammation (a hall mark for asthma) but somewhat surprisingly, clinical trials in children have not consistently found benefit from adding FENO to a symptom-based approach to ICS treatment in children. There are a number of reasons why FENO has apparently failed to translate from promising biomarker to clinically useful tool, and one reason may be a lack of understanding of what merits a significant intrasubject change in FENO. This review describes the rise and apparent fall of FENO as biomarker for asthma and then focuses on more recent evidence which suggest that FENO may prove to have a role in the management of childhood asthma, and in particular preventing exacerbations.

AB - Childhood asthma is a common chronic condition. Approximately five percent of all children in western countries are prescribed treatment with inhaled corticosteroids (ICS) to prevent asthma symptoms. Current guidelines advocate titrating ICS dose to symptoms but this approach is not without problem, e.g. how to discern asthmatic from non-asthmatic symptoms? And when to reduce ICS dose? This review describes the strengths and weaknesses of fractional exhaled nitric oxide (FENO) as an objective index for individualising asthma control in children. Epidemiological and mechanistic evidence suggest that FENO should be a promising biomarker for eosinophilic airway inflammation (a hall mark for asthma) but somewhat surprisingly, clinical trials in children have not consistently found benefit from adding FENO to a symptom-based approach to ICS treatment in children. There are a number of reasons why FENO has apparently failed to translate from promising biomarker to clinically useful tool, and one reason may be a lack of understanding of what merits a significant intrasubject change in FENO. This review describes the rise and apparent fall of FENO as biomarker for asthma and then focuses on more recent evidence which suggest that FENO may prove to have a role in the management of childhood asthma, and in particular preventing exacerbations.

KW - asthma

KW - child

KW - nitric oxide

KW - respiratory symptoms

U2 - 10.1016/j.prrv.2014.07.005

DO - 10.1016/j.prrv.2014.07.005

M3 - Article

C2 - 25182668

VL - 16

SP - 88

EP - 96

JO - Paediatric Respiratory Reviews

JF - Paediatric Respiratory Reviews

SN - 1526-0542

IS - 2

ER -